Kevin Dennis Green Sells 27,796 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 27,796 shares of Cerus stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $2.01, for a total value of $55,869.96. Following the completion of the transaction, the chief financial officer directly owned 1,168,095 shares in the company, valued at approximately $2,347,870.95. This represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Cerus Price Performance

Shares of CERS stock remained flat at $1.93 during trading hours on Monday. The stock had a trading volume of 2,029,960 shares, compared to its average volume of 1,640,307. Cerus Corporation has a one year low of $1.12 and a one year high of $2.96. The company has a quick ratio of 1.17, a current ratio of 1.73 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $370.89 million, a PE ratio of -24.13 and a beta of 1.51. The business’s fifty day simple moving average is $2.31 and its two-hundred day simple moving average is $1.86.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The business had revenue of $64.58 million for the quarter, compared to the consensus estimate of $59.31 million. As a group, research analysts expect that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Institutional Trading of Cerus

Institutional investors and hedge funds have recently modified their holdings of the company. Cibc World Markets Corp acquired a new position in shares of Cerus in the fourth quarter valued at $25,000. CIBC Bancorp USA Inc. acquired a new stake in Cerus during the third quarter worth $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in Cerus during the first quarter worth $32,000. Aquatic Capital Management LLC bought a new stake in Cerus in the 3rd quarter valued at $35,000. Finally, MML Investors Services LLC bought a new stake in Cerus in the 4th quarter valued at $37,000. 78.37% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CERS has been the topic of several research analyst reports. Wall Street Zen lowered shares of Cerus from a “buy” rating to a “hold” rating in a research report on Saturday. TD Cowen reaffirmed a “buy” rating on shares of Cerus in a research report on Monday, January 12th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cerus has an average rating of “Hold”.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.